Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Medimmune
Evaluate
September 22, 2016
Bubble stocks top the takeover premium charts
August 24, 2016
Few M&A teams venture beyond domestic borders
May 13, 2016
Payday approaches for Melinta's backers
October 20, 2015
Interview – Karolinska focuses, but not on early-stage medtech
September 18, 2015
Buying in growth beats innovation for pharma
June 30, 2015
Celgene goes for broke
November 05, 2014
Definiens shines a light on growing importance of biomarkers
June 19, 2014
Astra makes quiet progress with respiratory pipeline
June 18, 2014
Pfizer partners with Cellectis, but why not buy the company?
April 07, 2014
Daiichi’s ill-timed Indian foray ends in minority Sunbaxy stake
January 14, 2014
Merck catches Bristol with surprise PD-1 filing
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics